Based on the protective effect of higher genetically determined CSF EPO levels on WMH volume, potential repositioning of EPO analogs crossing the BBB and studied in phase II clinical trials for other indications (depression, neuropathy) is a compelling example. The gene discussed is EPO; the disease is depressive symptom measurement.